Life-changing therapies to help people build families and live better lives
At Ferring, we are committed to helping people build families and live better lives. In the United States, Ferring is a leader in reproductive medicine and maternal health, uro-oncology and in specialty areas within gastroenterology, including microbiome therapeutics, and orthopaedics.
Believing in the power of research
Each of us at Ferring contribute to providing innovative solutions to help people live better lives. We devote significant research and development investment to new therapeutics, life cycle management and next generation healthcare solutions.
Join us
At Ferring Pharmaceuticals we highly value an attractive working environment that motivates our employees and stimulates the creative abilities and initiative of both individuals and teams. With over 6,000 employees in more than 50 countries, we are able to draw upon a large multicultural setting to enrich the work of our staff on all levels.
Helping people live better lives
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives.
Ferring is a leader in reproductive medicine and maternal health, uro-oncology and in specialty areas within gastroenterology, including microbiome therapeutics, and orthopaedics.
News
-
Ferring Presents New Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at ACG 2024
-Real-world analyses evaluated the effectiveness of REBYOTA in patients with GI conditions or comorbidities as well as those who received therapy at home or in a clinic Interim data from a third ana...
-
Ferring Pharmaceuticals Illustrates Strong Commitment to Advancing Fertility Care at 2024 American Society for Reproductive Medicine Annual Congress
-Four abstracts, including two oral and two poster presentations, highlight Ferring’s dedication and multi-focus approach to advancing fertility care Parsippany, NJ – October 18, 2024 – Ferrin...
-
Ferring Presents Real-World Outcomes Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at IDWeek 2024
-New outcomes analyses evaluated efficacy and safety of REBYOTA in patients with recurrent C. diff infection in a real-world setting Patients were followed after receiving REBYOTA at home or in a cl...